pico in mCRC - The neurotoxicity profile for Pico is much better compared to Oxali based on ASCO presentation. So even a slightly equal efficacy should be good news for Pico. Median PFS was close in the data presented at ASCO. I think the CEO said they were going to present more PFS data today.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.